Be Bio: Clinical Stage Company Closes $92 Million (Series C)
By Amit Chowdhry ● Jan 25, 2025
Be Biopharma, Inc. (Be Bio), a leader in B Cell Medicines (BCMs), announced the closing of its $92 million Series C financing. The funding round includes participation from new investor Nextech with existing investors, including ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures. In connection with the funding, Melissa McCracken, Ph.D. of Nextech will join Be Bio’s Board of Directors.